Table S1. Primer sequences.

Gene	Primers (5'-3')	Size (bp)
miR-9-1	F: GAAATGTCGTTCGAATTAGTGAG	123
	R: GAAAAAACCGACCTCACGA	
	P: GGTGTTGGTTAGTTTTCGCGGTTTTAGTTTTTC -6FAM	
miR-9-2	F: CGTTGTCGGAGATTATTTGTTG	177
	R: ATACCGAAAAATAATCGTCCA	
	P: ATTTTGAAGGTAATAGATTTCGTTTGGATGTTTTAGTCGC -Y	Y
miR-9-3	F: TGTGCGTGTGTTTGTTTATTT	135
	R: CTTAACCAATACCGCTACCG	
	P: TTCGGGTACGGCGTTCGTTTAGGTTTTCG -DFO	
АСТВ	F: TGGTGATGGAGGAGGTTTAGTAAGT	133
	R: AACCAATAAAACCTACTCCTCCCTTAA	
	P: ACCACCACCCAACACACAATAACAAACACA -CY5	

(\mathbf{a})) miR-9	quantitative	MSP

bp, base pairs; F, Forward primer; R, Reverse primer; P, probe

(b) TaqMan quantitative RT-PCR

Gene	Primers (5'-3')	Size (bp)
CDH1	F: TTGACGCCGAGAGCTACAC	93
	R: GACCGGTGCAATCTTCAAA	
	P: GCGTCCTGGGCAGAGT -6FAM	
CDH2	F: CCACCTTAAAATCTGCAGGC	100
	R: GTGCATGAAGGACAGCCTCT	
	P: GGAAAAAGAAAAGTACAATATGAGAGCAGT -6FAM	
snRNP U1A	F: TCCTCACCAACCTGCCAGA	72
	R: TGAAGCCAGGGAACTGATTGA	
	P: AGACCAACGAGCTCATGCTGTCCATG -6FAM	
TWIST1	F: GTCCGCGTCCCACTAGC	90
	R: TCCATTTTCTCCTTCTCGGAA	
	P: GCAGGGCCGGAGACCTA -6FAM	
hn hasa naira E	Forward primer: P. Powerse primer: P. probe	

bp, base pairs; F, Forward primer; R, Reverse primer; P, probe

(c) TWIST 3'UTR cloning & mutagenesis

Gene	Primers (5'-3')
3'UTR-TWIST1	F: TCGAGAGCTCTA GCCGGAGACCTAGATGTCATTGTTTC
	R: ACTGCTCGAGTA GCCCGTCTGGGAATCACTGTC
3'UTR-TWIST1_mut	F: tctTTTTCTTGGAAATTAGAAGAGC
	R: aaccCATATATTTTTATTTTTAGTTATCCAG

bp, base pairs; F, Forward primer; R, Reverse primer; restriction site (F: SacI, R: XhoI); lower case: induced mutation

were either positive for HPV16 or HPV18, were included. * p < 0.05.				
Comparison	p-value	Direction		
<u>by HPV type:</u>				
HPV16: SCC (n=145) vs AC (n=27)	0.001 *	higher in SCC		
HPV18: SCC (n=28) vs AC (n=11)	0.386	higher in SCC		
<u>by histotype:</u>				
SCC: HPV16 (n=145) vs HPV18 (n=28)	0.209	higher in HPV18		
AC: HPV16 (n=27) vs HPV18 (n=11)	0.021 *	higher in HPV18		

Table S2. Expression of miR-9-5p in whole miRNome sequencing data from the TCGA depository [32]. Data of 211 cervical carcinomas, which were either positive for HPV16 or HPV18, were included. * p < 0.05.

Table S3. Correlation of miR-9-5p expression with expression of TWIST1, CDH1, and CDH2 per histotype. 200 cervical carcinomas were included, for which both whole miRNome and whole transcriptome sequencing data from the TCGA depository was available [32]. Spearman correlation coefficient rho and the associated p-value were assessed. # p < 0.1, * p < 0.05.

Spearman correlation	earman correlation TWIST1		CDH1		CDH2	
	Rho	p-value	Rho	p-value	Rho	p-value
SCC (n=161)	-0.138	0.082 #	0.031	0.696	-0.167	0.035 *
AC (n=39)	0.367	0.022 *	-0.117	0.478	0.281	0.083 #



Figure S1. Effect of miR-9-5p on IL6 and FOXO3 in cervical cancer cell lines. Expression of (**a**) IL6 and (**b**) FOXO3 mRNAs upon overexpression of miR-9-5p in cervical cancer cell lines SiHa, CaSki, and HeLa relative to the respective negative control. FOXO3 melting curve analysis indicated aspecific products and FOXO3 expression data should therefore be interpreted with caution.